Screening and early diagnosis of hepatocellular carcinoma

V.T. Kiriienko, I.A. Zaitsev, V.V. Hrushkevych, V.V. Potii

Abstract


The article presents the current possibilities for screening and early diagnosis of hepatocellular carcinoma with imaging techniques, non-invasive serological and immunohistochemical markers, as well as indications and accuracy for morphological study of focal lesions of the liver in patients of risk group.

Keywords


hepatocellular carcinoma; primary liver cancer; screening; early diagnosis; alfa-fetoprotein; biopsy

References


Siegel R, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442.

Alavian SM, Haghbin H. Relative Importance of Hepatitis B and C Viruses in Hepatocellular Carcinoma in EMRO Countries and the Middle East. Hepat Mon. 2016 Mar 6;16(3):e35106. doi: 10.5812/hepatmon.35106.

Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN2012. Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210.

Tejeda-Maldonado J, García-Juárez I, Aguirre-Valadez J. Diagnosis and treatment of hepatocellular carcinoma: An update.World J Hepatol. 2015 Mar 27;7(3):362-76. doi: 10.4254/wjh.v7.i3.362.

El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014 Nov;60(5):1767-75. doi: 10.1002/hep.27222.

Fedorenko ZP, Michailovich YYo, Goulak LO, et al, authors; Kolesnik OO, editor. Cancer in Ukraine 2014 - 2015: Bulletin of national cancer registry of Ukraine. Kyiv; 2016. 144 p.

Sunkara V, Hebert JR. The application of the mortality-to-incidence ratio for the evaluation of cancer care disparities globally. Cancer. 2016 Feb 1;122(3):487-8. doi: 10.1002/cncr.29746.

Sunkara V, Hebert JR. The colorectal cancer mortality-to-incidence ratio as an indicator of global cancer screening and care. Cancer. 2015 May 15;121(10):1563-9. doi: 10.1002/cncr.29228.

Chen SL, Wang SC, Ho CJ, et al. Prostate cancer mortality-to-incidence ratios are associated with cancer care disparities in 35 countries. Sci Rep. 2017 Jan 4;7:40003. doi: 10.1038/srep40003.

Wang SC, Sung WW, Kao YL, et al. The gender difference and mortality-to-incidence ratio relate to health care disparities in bladder cancer: national estimates from 33 countries. Sci Rep. 2017 Jun 28;7(1):4360. doi: 10.1038/s41598-017-04083-z.

Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 1981 Nov 21;2(8256):1129-33.

Singal AG, Pillai A, Tiro A. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014 Apr 1;11(4):e1001624. doi: 10.1371/journal.pmed.1001624.

Siegel R, Naishadham D, Jemal A. Cancer statistics 2013. CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166.

European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2012 Apr;56(4):908-43. doi: 10.1016/j.jhep.2011.12.001.

Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006 Oct;45(4):529-38. doi: 10.1016/j.jhep.2006.05.013.

Parkin D.M. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006 Jun 15;118(12):3030-44. doi: 10.1002/ijc.21731.

Tejeda-Maldonado J, García-Juárez I, Aguirre-Valadez J, et al. Diagnosis and treatment of hepatocellular carcinoma: an update. World J Hepatol. 2015 Mar 27;7(3):362-76. doi: 10.4254/wjh.v7.i3.362.

Rosenthal E, Poiree M, Pradier C, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS. 2003 Aug 15;17(12):1803-9. doi: 10.1097/01.aids.0000072671.21517.44.

Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006 Oct;45(4):529-38. doi: 10.1016/j.jhep.2006.05.013.

Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004 Oct 7;351(15):1521-31. DOI: 10.1056/NEJMoa033364.

Stewart CJ, Coldewey J, Stewart IS. Comparison of fine needle aspiration cytology and needle core biopsy in the diagnosis of radiologically detected abdominal lesions. J Clin Pathol. 2002 Feb;55(2):93-7.

Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol. 2003 Mar;98(3):679-90.

El-Serag HB. Epidemiology of hepatitis C-related hepatocellular carcinoma. Medscape Gastroenterology. 2007. Available from: http: //www.medscape.com/viewarticle/560012.

Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999;19(3):271-85. doi: 10.1055/s-2007-1007117.

Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199.

Wörns MA, Weinmann A, Pfingst K, et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol. 2009 May-Jun;43(5):489-95. doi: 10.1097/MCG.0b013e31818ddfc6.

Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and non-cirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med. 1999 Aug 3;131(3):174-81.

CDC/National Center for Health Statistics. National Health and Nutrition Examination Survey. Available from: https://www.cdc.gov/nchs/nhanes/index.htm. Accessed: February 19, 2009.

Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013 Mar 5;158(5 Pt 1):329-37. doi: 10.7326/0003-4819-158-5-201303050-00005.

Levy I, Greig PD, Gallinger S, Langer B, Sherman M. Resection of hepatocellular carcinoma without preoperative tumor biopsy. Ann Surg. 2001 Aug;234(2):206-9.

Gurusamy KS, Wilson R, Koretz RL, et al. Is Sustained Virological Response a Marker of Treatment Efficacy in Patients with Chronic Hepatitis C Viral Infection with No Response or Relapse to Previous Antiviral Intervention? PLoS One. 2013 Dec 12;8(12):e83313. doi: 10.1371/journal.pone.0083313.

Volk ML, Marrero JA. Early detection of liver cancer: diagnosis and management. Curr Gastroenterol Rep. 2008 Feb;10(1):60-6.

Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004 Nov;127(5 Suppl 1):S35-50.

Shen YC, Hsu C, Cheng CC, Hu FC, Cheng AL. A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regression. Oncology. 2012;82(5):275-89. doi: 10.1159/000337293.

Shen YC, Hsu C, Cheng CC, Hu FC, Cheng AL. A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regression. Oncology. 2012;82(5):275-89. doi: 10.1159/000337293.

Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013 Jul;47 Suppl:S2-6. doi: 10.1097/MCG.0b013e3182872f29.

Torres DM, Harrison SA. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma. Semin Liver Dis. 2012 Feb;32(1):30-8. doi: 10.1055/s-0032-1306424.

Wong R, Corley DA. Racial and ethnic variations in hepatocellular carcinoma incidence within the United States. Am J Med. 2008 Jun;121(6):525-31. doi: 10.1016/j.amjmed.2008.03.005.

McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011 May;15(2):223-43, vii-x. doi: 10.1016/j.cld.2011.03.006.

Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005 Nov;42(5):1208-36. doi: 10.1002/hep.20933.

Takamatsu S, Noguchi N, Kudoh A, et al. Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma. Hepatogastroenterology. 2008 Mar-Apr;55(82-83):609-14.

Blonski W, Kotlyar DS, Forde KA. Non-viral causes of hepatocellular carcinoma. World J Gastroenterol. 2010 Aug 7;16(29):3603-15.

Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004 Nov;127(5 Suppl 1):S35-50.

Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010 Jun;51(6):2193-213. doi: 10.1002/hep.23584.

Beaton MD, Adams PC. Prognostic factors and survival in patients with hereditary hemochromatosis and cirrhosis. Can J Gastroenterol. 2006 Apr;20(4):257-60.

Bartlett DL, Di Bisceglie AM, Dawson LA. Cancer of the liver. In: Vincent T. DeVita Jr., Theodore S. Lawrence, Steven A. Rosenberg, editors. DeVita, Hellman, and Rosenberg's cancer: principles & practice of oncology. 8th ed. United States, Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2008. 2 v. (lxxii, 1485, I-112 p.) : ill., port.

Song DS, Bae SH. Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period. Clin Mol Hepatol. 2012 Sep;18(3):258-67. doi: 10.3350/cmh.2012.18.3.258.

Davenport MS, Khalatbari S, Liu PS, et al. Repeatability of diagnostic features and scoring systems for hepatocellular carcinoma by using MR imaging. Radiology. 2014 Jul;272(1):132-42. doi: 10.1148/radiol.14131963.

Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199.

European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2012 Apr;56(4):908-43. doi: 10.1016/j.jhep.2011.12.001.

Arif-Tiwari H, Kalb B, Chundru S, et al. MRI of hepatocellular carcinoma: an update of current practices. Diagn Interv Radiol. 2014 May-Jun;20(3):209-21. doi: 10.5152/dir.2014.13370.

Singal AG, Conjeevaram HS, Volk ML, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev. 2012 May;21(5):793-9. doi: 10.1158/1055-9965.EPI-11-1005.

Digumarthy SR, Sahani DV, Saini S. MRI in detection of hepatocellular carcinoma (HCC). Cancer Imaging. 2005 Apr 13;5:20-4. doi: 10.1102/1470-7330.2005.0005.

Sporea I, Badea R, Popescu A, et al. Contrast-Enhanced Ultrasound (CEUS) for the evaluation of focal liver lesions — a prospective multicenter study of its usefulness in clinical practice. Ultraschall Med. 2014 Jun;35(3):259-66. doi: 10.1055/s-0033-1355728.

Sporea I, Martie A, Bota S, Sirli R, Popescu A, Dănila M. Characterization of focal liver lesions using contrast enhanced ultrasound as a first line method: a large monocentric experience. J Gastrointestin Liver Dis. 2014 Mar;23(1):57-63.

European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012 Apr;56(4):908-43. doi: 10.1016/j.jhep.2011.12.001.

Kubota K, Ina H, Okada Y, Irie T. Growth rate of primary single hepatocellular carcinoma: determining optimal screening interval with contrast enhanced computed tomography. Dig Dis Sci. 2003 Mar;48(3):581-6.

Trinchet JC, Chaffaut C, Bourcier V, et al; Grouped’Etudeet de Traitement du CarcinomeHépatocellulaire (GRETCH). Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology. 2011 Dec;54(6):1987-97. doi: 10.1002/hep.24545.

Singal A, Volk ML, WaljeeA, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009 Jul;30(1):37-47. doi: 10.1111/j.1365-2036.2009.04014.x.

Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2008 Dec;6(12):1418-24. doi: 10.1016/j.cgh.2008.08.005.

Yu NC, Chaudhari V, Raman SS, et al. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol. 2011 Feb;9(2):161-7. doi: 10.1016/j.cgh.2010.09.017.

Lee KH, O’Malley ME, Haider MA, Hanbidge A. Triple-phase MDCT of hepatocellular carcinoma. AJR Am J Roentgenol. 2004 Mar;182(3):643-9. doi: 10.2214/ajr.182.3.1820643.

Solomon R. Contrast-induced acute kidney injury: is there a risk after intravenous contrast? Clin J Am Soc Nephrol. 2008 Sep;3(5):1242-3. doi: 10.2215/CJN.03470708.

Zhao YJ, Ju Q, Li GC. Tumor markers for hepatocellular carcinoma (Review). Mol Clin Oncol. 2013 Jul;1(4):593-598. doi: 10.3892/mco.2013.119.

Yamashita T, Forgues M, Wang W, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008 Mar 1;68(5):1451-61. doi: 10.1158/0008-5472.CAN-07-6013.

Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med. 2010;61:317-28. doi: 10.1146/annurev.med.080608.100623.

Hoshida Y, Nijman SM, Kobayashi M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009 Sep 15;69(18):7385-92. doi: 10.1158/0008-5472.CAN-09-1089.

Lok AS, Sterling RK, Everhart JE, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010 Feb;138(2):493-502. doi: 10.1053/j.gastro.2009.10.031.

Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta. 2008 Sep;395(1-2):19-26. doi: 10.1016/j.cca.2008.05.010.

Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004 Jul;130(7):417-22.

Singhal A, Jayaraman M, Dhanasekaran DN, Kohli V. Molecular and serum markers in hepatocellular carcinoma: predictive tools for prognosis and recurrence. Crit Rev Oncol Hematol. 2012 May;82(2):116-40. doi: 10.1016/j.critrevonc.2011.05.005.

Nakamura S, Nouso K, Sakaguchi K, et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol. 2006 Sep;101(9):2038-43.

Baek YH, Lee JH, Jang JS, et al. Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP. Hepatogastroenterology. 2009 May-Jun;56(91-92):763-7.

Yamamoto K, Imamura H, Matsuyama Y, et al. AFP, AFP-L3, DCP and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol. 2010 Dec;45(12):1272-82. doi: 10.1007/s00535-010-0278-5.




DOI: https://doi.org/10.22141/2312-413x.6.2.2018.131091

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 ACTUAL INFECTOLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта